The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated …

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

~Estimated

~$10 – $7,500

AmgenNCT06072482

Phase 1

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerab…

Systemic SclerosisIdiopathic Inflammatory MyopathiesAntineutrophil Cytoplasmic Antibody-Associated Vasculitis+1 more

~Estimated

~$10 – $8,750

Nkarta, Inc.NCT06733935